image
Healthcare - Medical - Devices - NYSE - US
$ 229.4
1.68 %
$ 6.44 B
Market Cap
-3.51
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one BIO stock under the worst case scenario is HIDDEN Compared to the current market price of 229 USD, Bio-Rad Laboratories, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one BIO stock under the base case scenario is HIDDEN Compared to the current market price of 229 USD, Bio-Rad Laboratories, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one BIO stock under the best case scenario is HIDDEN Compared to the current market price of 229 USD, Bio-Rad Laboratories, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart BIO

image
$380.0$380.0$360.0$360.0$340.0$340.0$320.0$320.0$300.0$300.0$280.0$280.0$260.0$260.0$240.0$240.0$220.0$220.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
2.57 B REVENUE
-3.92%
269 M OPERATING INCOME
-20.37%
-99.4 M NET INCOME
84.40%
455 M OPERATING CASH FLOW
21.41%
-160 M INVESTING CASH FLOW
-792.76%
-219 M FINANCING CASH FLOW
48.60%
668 M REVENUE
2.74%
58.4 M OPERATING INCOME
-9.41%
-716 M NET INCOME
-109.58%
124 M OPERATING CASH FLOW
-24.12%
-30.5 M INVESTING CASH FLOW
45.10%
-26.2 M FINANCING CASH FLOW
72.65%
Balance Sheet Bio-Rad Laboratories, Inc.
image
Current Assets 1.21 B
Cash & Short-Term Investments 1.18 B
Receivables 0
Other Current Assets 30.7 M
Non-Current Assets 5.65 B
Long-Term Investments 4.84 B
PP&E 689 M
Other Non-Current Assets 117 M
17.17 %70.62 %10.05 %Total Assets$6.9b
Current Liabilities 468 M
Accounts Payable 122 M
Short-Term Debt 42.9 M
Other Current Liabilities 303 M
Non-Current Liabilities 2.33 B
Long-Term Debt 131 M
Other Non-Current Liabilities 2.2 B
4.38 %10.83 %4.70 %78.56 %Total Liabilities$2.8b
EFFICIENCY
Earnings Waterfall Bio-Rad Laboratories, Inc.
image
Revenue 2.57 B
Cost Of Revenue 1.19 B
Gross Profit 1.38 B
Operating Expenses 1.11 B
Operating Income 269 M
Other Expenses 368 M
Net Income -99.4 M
3b3b3b3b2b2b2b2b1b1b500m500m00(500m)(500m)3b(1b)1b(1b)269m(368m)(99m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
53.73% GROSS MARGIN
53.73%
10.48% OPERATING MARGIN
10.48%
-71.86% NET MARGIN
-71.86%
-28.07% ROE
-28.07%
-19.69% ROA
-19.69%
3.29% ROIC
3.29%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Bio-Rad Laboratories, Inc.
image
600m600m500m500m400m400m300m300m200m200m100m100m00(100m)(100m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -99.4 M
Depreciation & Amortization 152 M
Capital Expenditures -189 M
Stock-Based Compensation 0
Change in Working Capital -621 M
Others 444 M
Free Cash Flow 266 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Bio-Rad Laboratories, Inc.
image
Wall Street analysts predict an average 1-year price target for BIO of $400 , with forecasts ranging from a low of $400 to a high of $400 .
BIO Lowest Price Target Wall Street Target
400 USD 74.37%
BIO Average Price Target Wall Street Target
400 USD 74.37%
BIO Highest Price Target Wall Street Target
400 USD 74.37%
Price
Max Price Target
Min Price Target
Average Price Target
400400380380360360340340320320300300280280260260240240220220May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 14
6. Ownership
Insider Ownership Bio-Rad Laboratories, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Should You Continue to Hold Bio-Rad Stock in Your Portfolio? BIO continues to attract investors' attention due to its robust performance in the ddPCR platform. zacks.com - 2 weeks ago
BIO-key Trims 2024 Net Loss 49% to $4.3M, Reflecting Higher Gross Margin and Lower Operating Costs, Offsetting 11% Revenue Decrease Due to Business Transition; Hosts Investor Call Today at 10am ET BIO-key Trims 2024 Net Loss 49% to $4.3M, Reflecting Higher Gross Margin & Lower Operating Costs, Offsetting 11% Revenue Decrease From Business Transition. globenewswire.com - 3 weeks ago
BIO-key Completes Initial Biometric-Based Identity and Access Management Deployment for New International Defense Agency Customer in Record Time BIO-key (BKYI) Completes Initial Biometric-Based Identity and Access Management Deployment for New International Defense Agency Customer in Record Time. globenewswire.com - 3 weeks ago
Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts IRVINE, Calif., March 24, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its fourth quarter results: Fellow Shareholders, Our dynamic team is making swift progress toward delivering a regulated organ transplant rejection monitoring test kit to the market next year. prismmediawire.com - 3 weeks ago
Identity, Access Management & Biometric Solutions Provider BIO-key International Hosts Q4 Investor Call Thursday, March 27th at 10am ET Identity, Access Management & Biometric Solutions Provider BIO-key International (Nasdaq: BKYI) Hosts Q4 Investor Call Thursday, March 27th at 10am ET. globenewswire.com - 1 month ago
Enveric Biosciences Participating in BIO-Europe Spring® CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced its participation in BIO-Europe Spring®, which is being held in Milan, Italy, March 17-19, 2025. During the Spring partnering event, members of Enveric's management team are conducting one-on-one meeting. businesswire.com - 1 month ago
BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUE NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of bluebird bio, Inc. (NasdaqGS: BLUE) to Carlyle Group and SK Capital Partners, LP. Under the terms of the agreement, bluebird shareholders will receive $3.00 per share in cash and a contingent value right per share, entitling the holder to a payment of $6.84 in cash per contingent value right if blue. businesswire.com - 1 month ago
BIO-key Partners with California Ed Tech JPA to Make its Identity and Access Management Solutions Available to 195 Member Institutions Serving Over 2.6M Students BIO-key (BKYI) Partners with California Ed Tech JPA to Make Identity & Access Management Solutions Available to 195 Member Institutions and 2.6M Students. globenewswire.com - 1 month ago
Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring 2025 CHATHAM, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D. globenewswire.com - 1 month ago
Bio-Rad (BIO) International Revenue Performance Explored Review Bio-Rad's (BIO) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock. zacks.com - 1 month ago
BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUE NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of bluebird bio, Inc. (NasdaqGS: BLUE) to Carlyle Group and SK Capital Partners, LP. Under the terms of the agreement, bluebird shareholders will receive $3.00 per share in cash and a contingent value right per share, entitling the holder to a payment of $6.84 in cash per contingent value right if bluebird's curr. businesswire.com - 1 month ago
BIO Stock Might Rise Following the Offer to Acquire Stilla Bio-Rad offers to acquire all equity interests of Stilla Technology. The acquisition is expected to complement Bio-Rad's existing digital PCR portfolio. zacks.com - 2 months ago
8. Profile Summary

Bio-Rad Laboratories, Inc. BIO

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 6.44 B
Dividend Yield 0.00%
Description Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Contact 1000 Alfred Nobel Drive, Hercules, CA, 94547 https://www.bio-rad.com
IPO Date Feb. 27, 1980
Employees 7700
Officers Mr. Jonathan P. DiVincenzo President & Chief Operating Officer Matthew Werner Senior Vice President and Chief Compliance & Privacy Officer Ms. Anette Engelhardt Executive Vice President & President of the Clinical Diagnostics Group Ms. Colleen Corey Executive Vice President of Global Human Resources Lee Boyd Senior Vice President of Global Commercial Operations - Asia Pacific Mr. Michael Crowley Executive Vice President of Global Commercial Operations Mr. Yong Chung Vice President of Investor Relations Mr. James J. Barry Executive Vice President & President of Life Science Group Mr. Norman D. Schwartz Chairman & Chief Executive Officer Courtney C. Enloe Executive Vice President, General Counsel & Secretary